Jefferies reiterates Boston Scientific stock rating on growth outlook

NodeGuardian · 2026-03-30T00:00:34+00:00

Jefferies maintains a Buy rating on Boston Scientific Corp. with a $120 price target, citing undervaluation and strong growth prospects in interventional cardiology, despite recent challenges in electrophysiology sales.

NodeGuardian

2026-03-30 00:00:34

Abstract generation in progress

Jefferies has reiterated a Buy rating on Boston Scientific Corp. (NYSE: BSX) with a $120.00 price target, noting the company is undervalued according to InvestingPro data. The firm expects Boston Scientific’s interventional cardiology division to be a significant growth driver, targeting above a 10% market compound annual growth rate. Despite a recent miss in U.S. electrophysiology sales, the company’s strong revenue growth and strategic pipeline underscore Jefferies’ positive outlook.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes